Antibody-independent B cell functions play an important role in multiple sclerosis (MS) pathogenesis.
Introduction

MS is an inflammatory demyelinating disease of the central nervous system (CNS). Different clinical subtypes exist, including relapsing-remitting MS (RRMS) in which clinical relapses alternate with
remission (80-85%), secondary progressive MS (SPMS) with progressive neurological disease in 90% of RRMS patients within 25 years and primary progressive MS (PPMS) with a progressive course from the onset (10-15%) [1] . Research into the role of B cells in MS pathogenesis has mainly focused on the production of autoantibodies. Oligoclonal immunoglobulin bands in the cerebrospinal fluid (CSF) are used for diagnostic confirmation [2] . Several CNS autoantigens that are targeted by the humoral immune response in MS have been described, although disease specificity and pathologic potential of most of the reported autoantibodies is debatable [3] . Antibody-independent B cell functions have gained interest in regard to MS pathology due to the clinical benefit of the B cell depleting anti-CD20 monoclonal antibody rituximab in RRMS and more recently ocrelizumab in RRMS and even PPMS [4, 5] . As rituximab does not target antibody-secreting plasma cells, the observed decrease in gadoliniumenhancing lesions on magnetic resonance imaging (MRI) was not due to reduced serum and CSF antibody titers or altered oligoclonal antibodies [6, 7] . Instead, the decrease in CSF T cell numbers and peripheral Th1 and Th17 responses following B cell depletion indicated the importance of B cells in T cell regulation in MS pathology [6, 8] . as CD86 and CD80, that are necessary to obtain full APC potency [9] . Several in vitro studies have shown that human B cells can induce effective T cell responses towards both foreign and self antigens [10, 11] . In MS patients, peripheral B cells showed increased expression of CD80 and MHCII during active disease [12] . Memory B cells from the peripheral blood of some RRMS patients induced autoreactive T cell proliferation and IFN- production [13] . More information is available from studies using experimental autoimmune encephalomyelitis (EAE), in which B cells promoted the differentiation of myelin oligodendrocyte glycoprotein (MOG)-specific Th1 and Th17 cells [14] . Interestingly, mice selectively deficient in MHCII molecules on B cells were resistant to EAE induction and exhibited diminished Th1 and Th17 responses [15] . Moreover, B cell antigen presentation was proven to be crucial for maximal disease in EAE, further emphasizing the importance of B cells in driving CD4 + T cell autoreactivity [16] .
In this study, we measured B cell expression of costimulatory and human leukocyte antigen (HLA) Limburg. Clinical data are provided in Table 1 .
Flow cytometry was done using 52 HC and 74 MS patients, 41 untreated and 33 receiving immunomodulatory treatment, including IFN-β (n = 13), glatiramer acetate (n = 5), fingolimod (n = 7), natalizumab (n = 4) and others (n = 4). Paired CSF samples were collected from 20 out of 74 MS patients, of which 18 were untreated and 2 received IFN-β treatment. B cell proliferation assay was done for 5 untreated MS patients and 6 age-and gender-matched HC. B:T coculture assay was performed for treated (n = 10) and untreated (n = 9) MS patients and matched HC (n = 10). Treatment included IFN-β (n = 4), dimethylfumarate (n = 3) and teriflunomide (n = 3).
Cell isolation
PBMC were isolated from whole blood by density gradient centrifugation (Lympholyte, Cedarlane
Laboratories, Sanbio B.V., Uden, The Netherlands). Cells were collected by centrifugation of the CSF for 12 min at 250 g. CSF samples contaminated with red blood cells were excluded from analyses.
B cells were purified from PBMC using magnetic negative (STEMCELL Technologies SARL, Grenoble, France) or positive (Miltenyi Biotec B.V., Leiden, The Netherlands) selection. T cells were enriched by magnetic negative selection (STEMCELL Technologies SARL). Purity was confirmed on a FACSAria II flow cytometer (BD Biosciences, Erembodegem, Belgium). 
Flow cytometric analysis
B:T coculture assay
Purified B cells were loaded with 20 Lf/ml TT, 100 µg/ml MBP, 30 µg/ml MOG peptide 34-56 or 10 µg/ml CMV (Microbix, Ontario, Canada). Loaded or non-loaded irradiated (1500 Rad) B cells were cocultured 2:1 with autologous CFSE-labelled T cells. T or B cells were cultured separately to analyse non-specific proliferation, which was absent in all tested samples. PHA (Sigma-Aldrich) was included as a positive control. MHCII:TCR interactions were blocked in cocultures with TT using 5 µg/ml azidefree anti-HLA-DR (BD Biosciences), anti-HLA-A/B/C or isotype control antibody (Biolegend) for 3 untreated MS patients, 2 treated MS patients and 5 HC. After 9 days, T cell proliferation was measured by flow cytometry using anti-human CD3 allophycocyanin-Cy7 (Biolegend), CD19 PE-Cy7, CD4 PE-CF594, CD8 PE, CD25 allophycocyanin and 7-AAD (all from BD Biosciences). Analysis was done on a FACSAria II flow cytometer using FACSDiva software (both from BD Biosciences). The ΔPF (%) was calculated as described above. The stimulation index (SI) was calculated by dividing the mean proliferation in response to antigen by the mean background proliferation (CM). An antigenic T cell response was significant when ΔPF > 2% and SI > 1.5.
Cytokine ELISA
Production of IFN-, IL-4 and IL-17A in the B:T coculture assays was quantified using commercial ELISA (eBioscience, Vienna, Austria), following instructions of the manufacturer. Supernatants were diluted 8 1:10 for IFN-, 1:2 for IL-4 and 1:5 for IL-17A. Background OD (CM conditions) were subtracted from OD measured in the antigen-stimulated conditions.
Statistics
Statistical analyses were performed using Prism software (Graphpad). Comparison of multiple groups was done using ANOVA (Kruskal-Wallis) or Chi-square analysis of contingency tables. When comparing
Results
B cells of MS patients show an increased expression of costimulatory molecules
The ability of B cells to present (auto)antigens to T cells in MS patients was first studied by analysing the expression of antigen presentation (HLA) and costimulatory molecules on B cells from the peripheral blood, CSF and brain tissue of MS patients and controls. CD80, CD86, CD40 and HLA molecules are classical markers of B cell activation that work together to obtain full APC potency [9] . Although the MS population was older than the HC population, none of the observed effects was correlated with age (data not shown).
The observed increase in costimulatory molecule expression was even more pronounced on CSF B These results indicate an increased costimulatory molecule expression on peripheral blood B cells of MS patients, which was further enhanced on CNS infiltrating B cells. Thus, B cells of MS patients might be more efficient in the presentation of (auto)antigens to T cells.
B cells upregulate CD80 expression following antigen-specific stimulation
B cells were previously shown to increase CD80 and HLA-DR expression following polyclonal or CD40
ligand (CD40L) stimulation [19] . Using a B cell proliferation assay, we investigated upregulation of (Fig. 3C) .
The above results indicate that viral and autoantigen-specific B cells are present in the peripheral blood of both MS patients and HC. Following antigen-specific stimulation, these B cells upregulate CD80 expression, thereby further increasing their costimulatory capacity.
B cells of MS patients induce MBP-specific proinflammatory T cell proliferation
The antibody had no effect ( Fig. 5D-E) .
Next, we characterized the B cell induced T cell responses. Although the majority of proliferating T cells were CD4 + , little CD8 + T cell proliferation was evidenced against all tested antigens in both HC and MS patients (Fig. 6A ). The B cell induced CD4 + Th cell phenotype was analysed by measuring the production of IFN-, IL-17A and IL-4 in proliferating conditions of B:T cocultures using ELISA (Fig. 6B) . Immunomodulatory treatment reduced B cell induced T cell proliferation against TT and CMV.
Discussion
The success of rituximab and ocrelizumab in the treatment of RRMS and even PPMS has renewed interest into antibody-independent B cell functions in MS pathogenesis [4] [5] [6] 8] . showed that CD86 + naïve B cells were increased in untreated MS patients, which suggests increased activation of resting T cells [23] . Thus, the increase in CD86 + B cells in our study could also be restricted to naïve B cells, pointing to the activation of resting T cells, possibly by epitope spreading or the release of antigens from the CNS.
The elevated B cell costimulatory molecule expression was only evident in untreated MS patients, indicating that immunomodulatory treatment can reduce B cell costimulatory molecule expression to levels seen in HC. This probably is an indirect effect by the induction of a shift towards an antiinflammatory immune profile [24, 25] . IFN-β treated MS patients were already shown to present with a decreased percentage of CD80 + and CD86 + B cells [12, 23] . We now demonstrated that this decrease We next showed that B cells upregulate CD80 expression not only following polyclonal or CD40 ligand stimulation [19] , but also following antigen-specific stimulation. Thus, B cells of MS patients express increased levels of costimulatory molecules that can be further elevated by autoantigen recognition, rendering them highly potent activators of autoreactive T cells. As expected, similar B cell proliferation against TT was shown in HC and MS patients. Myelin-specific B cells were present both in HC and MS patients, which is in agreement with a study by Harp et al. [13] . Also the frequency of MBP-reactive B cells is similar between both studies.
The antigen presentation potential of B cells from MS patients was then functionally evaluated using a B:T coculture assay. Interestingly, B cell induced T cell proliferation towards MBP was evidenced in a proportion of MS patients and not in HC, although MBP-specific B cells were equally present in MS patients and HC. Previously, the frequency of MBP-reactive T cells was also indicated to be equal in the peripheral blood of HC and MS patients [28] . Thus, although the number of included patients was cells are a highly pathogenic CD4 + subtype that can induce and exacerbate disease in MS and EAE [29] .
Moreover, our findings correlate with the decreased Th1 and Th17 responses that were observed following B cell depletion with rituximab [6, 8] . T cell responses induced towards CMV and TT consisted mainly of IFN-, as expected [30, 31] .
An interesting finding was the decrease in the number of treated MS patients positive for B cell induced T cell proliferation towards TT and CMV. This is in agreement with the normal expression levels of costimulatory molecules on B cells from treated MS patients. Together, these results demonstrate that immunomodulatory treatment leads to a reduction in B cell induced proinflammatory T cell responses.
As this effect is most pronouncedly seen for TT and CMV, it is probably due to a general reduction in B cell functionality. shown to possess high antigen presentation potential in autoimmunity [13, 33] .
In conclusion, we have demonstrated the potential of peripheral B cells from MS patients to induce proinflammatory autoreactive T cell responses. These effects were reduced in MS patients under immunomodulatory treatment. Analysis of the B cell antigen presentation potential could lead to novel therapeutic opportunities for MS. 
